Literature DB >> 22327905

Nitric oxide synthase mediation of darbepoetin's cognitive benefits: a paradoxical effect?

Ganesan Venkatasubramanian.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22327905      PMCID： PMC3280637          DOI： 10.1038/npp.2011.270

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

1.  Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.

Authors:  Kosuke Kajitani; Michael Thorne; Michel Samson; George S Robertson
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

2.  Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.

Authors:  H Ehrenreich; D Hinze-Selch; S Stawicki; C Aust; S Knolle-Veentjer; S Wilms; G Heinz; S Erdag; H Jahn; D Degner; M Ritzen; A Mohr; M Wagner; U Schneider; M Bohn; M Huber; A Czernik; T Pollmächer; W Maier; A-L Sirén; J Klosterkötter; P Falkai; E Rüther; J B Aldenhoff; H Krampe
Journal:  Mol Psychiatry       Date:  2006-10-10       Impact factor: 15.992

3.  The nitric oxide synthase inhibitor, L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice.

Authors:  D Klamer; J A Engel; L Svensson
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

4.  A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function.

Authors:  A Reif; S Herterich; A Strobel; A-C Ehlis; D Saur; C P Jacob; T Wienker; T Töpner; S Fritzen; U Walter; A Schmitt; A J Fallgatter; K-P Lesch
Journal:  Mol Psychiatry       Date:  2006-03       Impact factor: 15.992

5.  Information processing deficits and nitric oxide signalling in the phencyclidine model of schizophrenia.

Authors:  Erik Pålsson; John Lowry; Daniel Klamer
Journal:  Psychopharmacology (Berl)       Date:  2010-08-28       Impact factor: 4.530

6.  A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.

Authors:  Yechiel Levkovitz; Shlomo Mendlovich; Sharon Riwkes; Yoram Braw; Hana Levkovitch-Verbin; Gilad Gal; Shmuel Fennig; Ilan Treves; Shmuel Kron
Journal:  J Clin Psychiatry       Date:  2009-11-03       Impact factor: 4.384
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.